Clinical trials

  • CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Incisional hernia
  • ENTRECTINIB for Locally advanced or metastatic solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements
  • DAZODALIBEP for Sjogren's syndrome | Sjögren's syndrome with moderate-to-severe systemic disease activity
  • Clindamycin, Tretinoin for Papulopustular acne
  • CAPIVASERTIB for Metastatic hormone-sensitive prostate cancer (PTEN deficiency)
  • Atezolizumab for Extensive-stage small cell lung cancer
  • IPTACOPAN for Atypical hemolytic uremic syndrome
  • CD19-targeted CAR T cells for Systemic sclerosis | Rheumatoid arthritis | Idiopathic inflammatory myopathy | Systemic lupus erythematosus
  • GLOFITAMAB for Diffuse large B-cell lymphoma
  • Durvalumab for Non-small cell lung cancer (stage III, N2) | Resectable locally advanced non-small cell lung cancer
  • ZANUBRUTINIB for Splenic marginal zone lymphoma
  • GIVINOSTAT for Duchenne muscular dystrophy